The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to review the evidence on the developments concerning access to antiretroviral drugs (ARVs) for the treatment of HIV/AIDS over the last 10 years in low- and middle-income countries, the factors that have contributed to progress, and the lessons that these offer for the future. Vice President Tim Wilsdon, Senior Consultant to CRA Dr. Jim Attridge, and Associate Hugh Kirkpatrick discuss these findings in their article. To read it, click here:
An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...